Skip to Main content Skip to Navigation
Journal articles

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward

Abstract : The Spin-D (Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease) and MiREnDa (Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease) trials taken together provide the reassuring demonstration that up to 25 mg/d spironolactone is reasonably safe, provided maintenance hemodialysis patients are properly monitored and investigators use a per-protocol therapeutic algorithm to manage hyperkalemia. These results should encourage and reassure the investigators of the 2 currently ongoing, large, international, major-outcome clinical trials, both of which are using spironolactone up to 25 mg/d: ACHIEVE (Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease trial; NCT03020303) and ALCHEMIST (ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial; NCT01848639). Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-02510924
Contributor : Philippe de Carvalho <>
Submitted on : Wednesday, March 18, 2020 - 12:11:50 PM
Last modification on : Monday, December 21, 2020 - 3:32:04 PM

Identifiers

Citation

Patrick Rossignol, Luc Frimat, Faiez Zannad. The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney International, Nature Publishing Group, 2019, 95 (4), pp.747-749. ⟨10.1016/j.kint.2018.12.006⟩. ⟨hal-02510924⟩

Share

Metrics

Record views

337